SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models.
about
Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.The miR-17/92 cluster is involved in the molecular etiology of the SCLL syndrome driven by the BCR-FGFR1 chimeric kinase.MicroRNA 339 promotes development of Stem Cell Leukemia/Lymphoma syndrome via downregulation of the BCL2L11 and BAX pro-apoptotic genes.
P2860
SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
SCLLTargeting FGFR1 to suppres ...... de novo AML in murine models.
@en
SCLLTargeting FGFR1 to suppres ...... de novo AML in murine models.
@nl
type
label
SCLLTargeting FGFR1 to suppres ...... de novo AML in murine models.
@en
SCLLTargeting FGFR1 to suppres ...... de novo AML in murine models.
@nl
prefLabel
SCLLTargeting FGFR1 to suppres ...... de novo AML in murine models.
@en
SCLLTargeting FGFR1 to suppres ...... de novo AML in murine models.
@nl
P2093
P2860
P356
P1433
P1476
SCLLTargeting FGFR1 to suppres ...... de novo AML in murine models.
@en
P2093
Aaron Bhole
Haiyan Qin
John K Cowell
Judith Karp
Mingqiang Ren
Sami Malek
P2860
P304
49733-49742
P356
10.18632/ONCOTARGET.10438
P407
P577
2016-07-06T00:00:00Z